Integra Lifesciences Holdings Corp (NASDAQ:IART) has been assigned an average rating of “Hold” from the eighteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $60.80.
Several research firms have recently commented on IART. Zacks Investment Research lowered shares of Integra Lifesciences from a “buy” rating to a “hold” rating in a research note on Tuesday, June 26th. Cantor Fitzgerald reissued a “hold” rating and issued a $59.00 price objective on shares of Integra Lifesciences in a research note on Wednesday, July 25th. BidaskClub lowered shares of Integra Lifesciences from a “buy” rating to a “hold” rating in a research note on Friday, July 27th. BTIG Research raised shares of Integra Lifesciences from a “neutral” rating to a “buy” rating and set a $69.00 price objective for the company in a research note on Thursday, July 26th. Finally, Citigroup lowered shares of Integra Lifesciences from a “buy” rating to a “neutral” rating and raised their price objective for the company from $64.00 to $66.00 in a research note on Monday, July 2nd.
In related news, insider Jeffrey Mosebrook sold 1,000 shares of Integra Lifesciences stock in a transaction that occurred on Friday, August 10th. The shares were sold at an average price of $62.42, for a total value of $62,420.00. Following the completion of the transaction, the insider now owns 3,085 shares in the company, valued at $192,565.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Stuart Essig sold 31,353 shares of Integra Lifesciences stock in a transaction that occurred on Tuesday, July 17th. The stock was sold at an average price of $63.50, for a total transaction of $1,990,915.50. Following the completion of the transaction, the director now owns 1,450,272 shares of the company’s stock, valued at approximately $92,092,272. The disclosure for this sale can be found here. Insiders sold 111,140 shares of company stock valued at $7,054,647 in the last quarter. 5.10% of the stock is owned by insiders.
Shares of IART opened at $61.96 on Wednesday. Integra Lifesciences has a 1-year low of $41.51 and a 1-year high of $67.50. The stock has a market cap of $5.61 billion, a price-to-earnings ratio of 31.77, a P/E/G ratio of 2.03 and a beta of 0.57. The company has a quick ratio of 2.27, a current ratio of 3.52 and a debt-to-equity ratio of 1.10.
Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, July 25th. The life sciences company reported $0.60 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.60. Integra Lifesciences had a net margin of 5.10% and a return on equity of 17.43%. The business had revenue of $366.20 million during the quarter, compared to analyst estimates of $368.08 million. During the same quarter last year, the firm posted $0.45 earnings per share. The business’s revenue for the quarter was up 29.8% compared to the same quarter last year. As a group, equities research analysts predict that Integra Lifesciences will post 2.4 earnings per share for the current fiscal year.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Read More: What are the Benefits of Index Funds?
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.